Avinger (AVGR) Scheduled to Post Earnings on Tuesday

Avinger (NASDAQ:AVGRGet Rating) will be posting its quarterly earnings results after the market closes on Tuesday, May 10th. Analysts expect Avinger to post earnings of ($1.21) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Avinger (NASDAQ:AVGRGet Rating) last posted its quarterly earnings results on Tuesday, March 22nd. The medical device company reported ($1.26) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.26). The company had revenue of $2.40 million for the quarter, compared to analysts’ expectations of $2.30 million. Avinger had a negative return on equity of 117.96% and a negative net margin of 171.88%. During the same quarter in the prior year, the company earned ($1.40) earnings per share. On average, analysts expect Avinger to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Shares of NASDAQ AVGR traded up $0.02 during trading on Tuesday, hitting $2.66. The company had a trading volume of 69 shares, compared to its average volume of 124,084. Avinger has a 52 week low of $2.45 and a 52 week high of $29.20. The business’s 50-day moving average is $4.90 and its 200 day moving average is $8.37. The company has a debt-to-equity ratio of 1.26, a current ratio of 5.48 and a quick ratio of 4.50.

Several brokerages have issued reports on AVGR. Zacks Investment Research raised shares of Avinger from a “sell” rating to a “hold” rating in a research note on Friday, April 22nd. B. Riley cut their target price on Avinger from $40.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, March 18th. Finally, StockNews.com cut Avinger from a “hold” rating to a “sell” rating in a report on Monday.

A number of large investors have recently modified their holdings of AVGR. Morgan Stanley increased its stake in Avinger by 52,153.2% in the third quarter. Morgan Stanley now owns 256,563 shares of the medical device company’s stock valued at $191,000 after purchasing an additional 256,072 shares in the last quarter. Citadel Advisors LLC boosted its holdings in shares of Avinger by 797.2% in the third quarter. Citadel Advisors LLC now owns 302,494 shares of the medical device company’s stock valued at $225,000 after buying an additional 268,778 shares during the period. Millennium Management LLC acquired a new position in shares of Avinger in the third quarter valued at approximately $69,000. Finally, Virtu Financial LLC boosted its holdings in shares of Avinger by 242.9% in the fourth quarter. Virtu Financial LLC now owns 227,579 shares of the medical device company’s stock valued at $102,000 after buying an additional 161,207 shares during the period.

Avinger Company Profile (Get Rating)

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Featured Articles

Earnings History for Avinger (NASDAQ:AVGR)

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.